<DOC>
	<DOCNO>NCT00499993</DOCNO>
	<brief_summary>The purpose protocol , evaluate lanreotide Autogel 120 mg effective control Growth Hormone ( GH ) secretion patient active acromegaly .</brief_summary>
	<brief_title>Efficacy Tolerability Lanreotide ( Autogel 120 mg ) Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Documented diagnosis active acromegaly , define serum GH level 5 µg/L , absence reduction serum GH level 1µg/L oral glucose tolerance test ( OGTT ) abnormal IGF1 value Patients undergone pituitary surgery le 3 month selection Patients previously treat radiotherapy Patients previously treat somatostatin analogue except presurgical treatment longer 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>